KR102215400B1 - C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제 - Google Patents
C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제 Download PDFInfo
- Publication number
- KR102215400B1 KR102215400B1 KR1020157028437A KR20157028437A KR102215400B1 KR 102215400 B1 KR102215400 B1 KR 102215400B1 KR 1020157028437 A KR1020157028437 A KR 1020157028437A KR 20157028437 A KR20157028437 A KR 20157028437A KR 102215400 B1 KR102215400 B1 KR 102215400B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- preparation
- alkyl
- added
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(C1)C1(C(NS(C1(*)CC1)(=O)=O)=O)NC(C(CC(C1)OC(CC2)CC2IIC(C(C2)C2C2)C2OC(NC2*)=O)N1C2=O)=O Chemical compound *C(C1)C1(C(NS(C1(*)CC1)(=O)=O)=O)NC(C(CC(C1)OC(CC2)CC2IIC(C(C2)C2C2)C2OC(NC2*)=O)N1C2=O)=O 0.000 description 3
- UVPITAVSERCLNN-KGYJZTGKSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(CCCC[C@H]([C@@H](C2)C2C2)[C@@H]2O2)(F)F)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC2=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(CCCC[C@H]([C@@H](C2)C2C2)[C@@H]2O2)(F)F)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC2=O UVPITAVSERCLNN-KGYJZTGKSA-N 0.000 description 2
- YCGNJFWMEASNEB-UHFFFAOYSA-N C=CC(c1nc(cccc2)c2nc1Cl)(F)F Chemical compound C=CC(c1nc(cccc2)c2nc1Cl)(F)F YCGNJFWMEASNEB-UHFFFAOYSA-N 0.000 description 1
- OGPSJBPLPKWKOA-CBBTXENCSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)OC(N2CCCCC[C@H](CCC3)[C@@H]3O3)=Nc(cc(cc4)C#N)c4C2=O)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC3=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)OC(N2CCCCC[C@H](CCC3)[C@@H]3O3)=Nc(cc(cc4)C#N)c4C2=O)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC3=O OGPSJBPLPKWKOA-CBBTXENCSA-N 0.000 description 1
- GLQGFMOZNJHADV-IJXVCPENSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2c(C(CCCC[C@H](C[C@H](C3)C#C)[C@@H]3O3)(F)F)nc(ccc(C#N)c4)c4n2)[C@@H]1C(N[C@](C1)([C@@H]1C(F)=[F])C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC3=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2c(C(CCCC[C@H](C[C@H](C3)C#C)[C@@H]3O3)(F)F)nc(ccc(C#N)c4)c4n2)[C@@H]1C(N[C@](C1)([C@@H]1C(F)=[F])C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC3=O GLQGFMOZNJHADV-IJXVCPENSA-N 0.000 description 1
- RNUJWADPOOWLLE-XZTBJTAPSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2c(C(CCCC[C@H]([C@@H](C3)[C@@H]3C3)[C@@H]3O3)(F)F)nc(ccc(OC(F)F)c4)c4n2)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC3=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2c(C(CCCC[C@H]([C@@H](C3)[C@@H]3C3)[C@@H]3O3)(F)F)nc(ccc(OC(F)F)c4)c4n2)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC3=O RNUJWADPOOWLLE-XZTBJTAPSA-N 0.000 description 1
- CHYGWKMGYNBONV-DMCPQOODSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2c(CCCCC[C@H](CCC3)[C@@H]3O3)nc(ccc(Cl)c4)c4n2)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC3=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2c(CCCCC[C@H](CCC3)[C@@H]3O3)nc(ccc(Cl)c4)c4n2)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC3=O CHYGWKMGYNBONV-DMCPQOODSA-N 0.000 description 1
- ZKPHHKUFXWYGMR-ZIOUVPKLSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C(C2)[C@@H]2C2)[C@@H]2O2)(F)F)[C@@H]1C(N[C@]1([C@H](CC(F)F)C1)C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC2=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C(C2)[C@@H]2C2)[C@@H]2O2)(F)F)[C@@H]1C(N[C@]1([C@H](CC(F)F)C1)C(NS(C1(C)CC1)(=O)=O)=O)=O)=O)NC2=O ZKPHHKUFXWYGMR-ZIOUVPKLSA-N 0.000 description 1
- YSUVJROBMKIZTJ-GWJNXHOTSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cc(cc3)OC)c3nc2CCCCC[C@H](C[C@H](C2)C#C)[C@@H]2O2)[C@@H]1C(O)=O)=O)NC2=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cc(cc3)OC)c3nc2CCCCC[C@H](C[C@H](C2)C#C)[C@@H]2O2)[C@@H]1C(O)=O)=O)NC2=O YSUVJROBMKIZTJ-GWJNXHOTSA-N 0.000 description 1
- NMKWMLVQMDGOKQ-VRZCWEDLSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(C=C=CCC[C@H]([C@@H](C2)C2C2)[C@@H]2O2)(F)F)[C@@H]1C(OC)=O)=O)NC2=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(C=C=CCC[C@H]([C@@H](C2)C2C2)[C@@H]2O2)(F)F)[C@@H]1C(OC)=O)=O)NC2=O NMKWMLVQMDGOKQ-VRZCWEDLSA-N 0.000 description 1
- OTQZNFGZDFXXEK-GNGPWBTGSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(CCCC[C@H](C[C@H](C2)C#C)[C@@H]2O2)(F)F)[C@@H]1C(OC)=O)=O)NC2=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(CCCC[C@H](C[C@H](C2)C#C)[C@@H]2O2)(F)F)[C@@H]1C(OC)=O)=O)NC2=O OTQZNFGZDFXXEK-GNGPWBTGSA-N 0.000 description 1
- IWNIZPIIPVMYQE-TYCUPIIGSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(CCCC[C@H]([C@H]2C=C[C@H]2C2)[C@@H]2O2)(F)F)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC2=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)Oc2nc(cccc3)c3nc2C(CCCC[C@H]([C@H]2C=C[C@H]2C2)[C@@H]2O2)(F)F)[C@@H]1C(N[C@](C1)([C@@H]1C(F)F)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC2=O IWNIZPIIPVMYQE-TYCUPIIGSA-N 0.000 description 1
- DCKUAHKIBNUXHX-UHFFFAOYSA-N CC(N1C)=Nc2ccccc2C1=O Chemical compound CC(N1C)=Nc2ccccc2C1=O DCKUAHKIBNUXHX-UHFFFAOYSA-N 0.000 description 1
- GPBBNPPLBQIADY-UHFFFAOYSA-N CC1(C)CCOCC1 Chemical compound CC1(C)CCOCC1 GPBBNPPLBQIADY-UHFFFAOYSA-N 0.000 description 1
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 1
- VMVIADZFLIXBSR-YUMQZZPRSA-N CC1C[C@H](C)O[C@@H](C)C1 Chemical compound CC1C[C@H](C)O[C@@H](C)C1 VMVIADZFLIXBSR-YUMQZZPRSA-N 0.000 description 1
- VMVIADZFLIXBSR-IEESLHIDSA-N CC1C[C@H](C)O[C@H](C)C1 Chemical compound CC1C[C@H](C)O[C@H](C)C1 VMVIADZFLIXBSR-IEESLHIDSA-N 0.000 description 1
- HULMGOUAVTTXRE-UHFFFAOYSA-N CS(c1nc(cc(cc2)Cl)c2nc1Cl)(=O)=O Chemical compound CS(c1nc(cc(cc2)Cl)c2nc1Cl)(=O)=O HULMGOUAVTTXRE-UHFFFAOYSA-N 0.000 description 1
- NTLSWNGQQCRIAH-FQTVUMPESA-N C[C@@H](C1)[C@H](C)[C@@H](CCC/C=C/c2nc(ccc(OC)c3)c3nc2O[C@H](C[C@H]2C(OC)=O)CN2C([C@H](C(C)(C)C)N2)=O)[C@@H]1OC2=O Chemical compound C[C@@H](C1)[C@H](C)[C@@H](CCC/C=C/c2nc(ccc(OC)c3)c3nc2O[C@H](C[C@H]2C(OC)=O)CN2C([C@H](C(C)(C)C)N2)=O)[C@@H]1OC2=O NTLSWNGQQCRIAH-FQTVUMPESA-N 0.000 description 1
- BIKZFNVUHYJTDD-BGDFYPHGSA-N C[C@@H](CC1)[C@@H](CCCCC(c2nc3ccccc3nc2O[C@H](C[C@H]2C(O)=O)CN2C([C@H](C(C)(C)C)N2)=O)(F)F)[C@@H]1OC2=O Chemical compound C[C@@H](CC1)[C@@H](CCCCC(c2nc3ccccc3nc2O[C@H](C[C@H]2C(O)=O)CN2C([C@H](C(C)(C)C)N2)=O)(F)F)[C@@H]1OC2=O BIKZFNVUHYJTDD-BGDFYPHGSA-N 0.000 description 1
- BEFYXEWMVXPACL-FTLREYFTSA-N C[C@H](C[C@H]1CC/C=C/C(c2nc(cccc3)c3nc2O[C@H](C[C@H]2C(OC)=O)CN2C([C@H](C(C)(C)C)N2)=O)(F)F)C[C@H]1OC2=O Chemical compound C[C@H](C[C@H]1CC/C=C/C(c2nc(cccc3)c3nc2O[C@H](C[C@H]2C(OC)=O)CN2C([C@H](C(C)(C)C)N2)=O)(F)F)C[C@H]1OC2=O BEFYXEWMVXPACL-FTLREYFTSA-N 0.000 description 1
- RTWAFFKTVWBHLQ-GWJNXHOTSA-N C[C@H](C[C@H]1CCCCCc2nc(ccc(OC)c3)c3nc2O[C@H](C[C@H]2C(OC)=O)CN2C([C@H](C(C)(C)C)N2)=O)C[C@H]1OC2=O Chemical compound C[C@H](C[C@H]1CCCCCc2nc(ccc(OC)c3)c3nc2O[C@H](C[C@H]2C(OC)=O)CN2C([C@H](C(C)(C)C)N2)=O)C[C@H]1OC2=O RTWAFFKTVWBHLQ-GWJNXHOTSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/02—Preparation by ring-closure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798961P | 2013-03-15 | 2013-03-15 | |
| US61/798,961 | 2013-03-15 | ||
| PCT/US2014/029765 WO2014145095A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic and bicyclic inhibitors of hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150130456A KR20150130456A (ko) | 2015-11-23 |
| KR102215400B1 true KR102215400B1 (ko) | 2021-02-10 |
Family
ID=50694007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157028437A Active KR102215400B1 (ko) | 2013-03-15 | 2014-03-14 | C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9617310B2 (https=) |
| EP (1) | EP2970335B1 (https=) |
| JP (2) | JP6511432B2 (https=) |
| KR (1) | KR102215400B1 (https=) |
| CN (1) | CN105073758B (https=) |
| AU (1) | AU2014233390B2 (https=) |
| BR (1) | BR112015021768A2 (https=) |
| CA (1) | CA2902569A1 (https=) |
| EA (1) | EA029088B1 (https=) |
| ES (1) | ES2735355T3 (https=) |
| IL (1) | IL240662A0 (https=) |
| MX (1) | MX2015013224A (https=) |
| SG (1) | SG11201507223TA (https=) |
| WO (1) | WO2014145095A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| CN105503751B (zh) * | 2015-12-22 | 2018-06-05 | 广西师范大学 | 一种喹喔啉衍生物的高效合成方法 |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| CN111004188B (zh) * | 2019-12-18 | 2021-04-20 | 安徽红杉生物医药科技有限公司 | Ns3/4a蛋白酶抑制剂中间体及其合成方法、应用 |
| CN111018795B (zh) * | 2019-12-25 | 2023-03-28 | 上海彩迩文生化科技有限公司 | 一种碱性条件下合成喹喔啉-3-酮的方法 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009005676A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3659102A (en) | 2000-12-12 | 2002-06-24 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| DE60324552D1 (en) | 2002-05-20 | 2008-12-18 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
| ES2361011T3 (es) | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
| ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| CN1788006A (zh) | 2003-04-18 | 2006-06-14 | 安南塔制药公司 | 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RS51974B (sr) | 2004-07-16 | 2012-02-29 | Gilead Sciences Inc. | Antivirusna jedinjenja |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| NZ565269A (en) * | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| ES2356776T3 (es) | 2005-10-11 | 2011-04-13 | Intermune, Inc. | Compuestos y métodos para inhibir la replicación del virus de la hepatitis. |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| BRPI0718161A2 (pt) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | Composto, composição farmacêutica, e, uso do composto. |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
| SG174809A1 (en) | 2007-05-03 | 2011-10-28 | Intermune Inc | Macrocyclic compounds useful as inhibitors of hepatitis c virus |
| JP2010526834A (ja) | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤 |
| US20090005387A1 (en) | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| WO2009042668A2 (en) | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Urea-containing peptides as inhibitors of viral replication |
| US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
| US20090111757A1 (en) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009070689A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| EP2222161A4 (en) | 2007-12-05 | 2011-09-28 | Enanta Pharm Inc | QUINOXALINYL DERIVATIVES |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| RU2515318C2 (ru) | 2007-12-21 | 2014-05-10 | Авила Терапьютикс, Инк. | Ингибиторы протеазы вируса гепатита с и их применение |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| JP2011510927A (ja) | 2008-01-24 | 2011-04-07 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖセリンプロテアーゼ阻害剤としての二フッ素化トリペプチド |
| ES2437147T3 (es) | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Inhibidores de serina proteasa macrocíclicos |
| CA2714604A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Macrocyclic hcv ns3 protease inhibitors |
| US8431733B2 (en) | 2008-03-12 | 2013-04-30 | Virobay, Inc. | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives |
| CN102015652A (zh) | 2008-03-20 | 2011-04-13 | 益安药业 | 作为丙型肝炎病毒抑制剂的氟化大环化合物 |
| WO2009142842A2 (en) | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US8211891B2 (en) | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
| EA019327B1 (ru) * | 2008-07-22 | 2014-02-28 | Мерк Шарп Энд Домэ Корп. | Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3 |
| KR101647520B1 (ko) | 2008-08-07 | 2016-08-10 | 에프. 호프만-라 로슈 아게 | 거대환식 화합물의 제조 방법 |
| CA2734744A1 (en) | 2008-08-20 | 2010-02-25 | Michael Eissenstat | Hcv protease inhibitors |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| PL2331538T3 (pl) | 2008-09-16 | 2014-09-30 | Boehringer Ingelheim Int | Krystaliczne postacie 2-tiazolylo-4chinolinyl-oksy-pochodnej, silnego inhibitora HCV |
| WO2010033466A1 (en) | 2008-09-16 | 2010-03-25 | Phenomix Corporation | Macrocyclic inhibitors of hepatitis c protease |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20110075019A (ko) | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | 치료용 항바이러스성 펩티드 |
| WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
| AU2009316472B2 (en) | 2008-11-20 | 2015-07-09 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus |
| CN102223875A (zh) | 2008-11-21 | 2011-10-19 | 贝林格尔.英格海姆国际有限公司 | 口服给药的强效hcv抑制剂的药物组合物 |
| US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| NZ592705A (en) | 2008-12-10 | 2013-02-22 | Achillion Pharmaceuticals Inc | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20110114582A (ko) | 2008-12-19 | 2011-10-19 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｃｖ ｎｓ３ 프로테아제 억제제 |
| JP5687631B2 (ja) | 2008-12-23 | 2015-03-18 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｈｃｖのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体 |
| US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
| WO2010135748A1 (en) | 2009-05-22 | 2010-11-25 | Sequoia Pharmaceuticals Inc. | Bimacrocyclic hcv ns3 protease inhibitors |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| EP2470189A4 (en) | 2009-08-27 | 2013-01-23 | Merck Sharp & Dohme | METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS |
| CN102741270B (zh) | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| US20110082182A1 (en) | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| US9193740B2 (en) | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
| CN104771364B (zh) | 2010-03-10 | 2018-05-25 | 艾伯维巴哈马有限公司 | 固体组合物 |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| JP2013528217A (ja) | 2010-06-07 | 2013-07-08 | アッヴィ・インコーポレイテッド | 大環状ｃ型肝炎セリンプロテアーゼ阻害薬 |
| WO2012019299A1 (en) | 2010-08-11 | 2012-02-16 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| US20120094897A1 (en) | 2010-09-15 | 2012-04-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| SG188618A1 (en) | 2010-09-21 | 2013-04-30 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
| WO2012047764A1 (en) | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2012054874A1 (en) | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2012061248A2 (en) | 2010-11-01 | 2012-05-10 | Rfs Pharma, Llc | Novel specific hcv ns3 protease inhibitors |
| JP6034802B2 (ja) | 2010-12-14 | 2016-11-30 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 大環状ラクタムの調製のための方法および中間体 |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012166459A1 (en) | 2011-05-27 | 2012-12-06 | Bristol-Myers Squibb Company | Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2857705A1 (en) | 2011-06-16 | 2012-12-20 | AB Pharma Ltd. | Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof |
| US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
| EP2744331A4 (en) | 2011-08-19 | 2015-01-21 | Merck Sharp & Dohme | METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN |
| US20140328799A1 (en) | 2011-10-31 | 2014-11-06 | Steven S. Carroll | Compositions useful for the treatment of viral diseases |
| EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| AU2013208024A1 (en) | 2012-01-12 | 2014-07-10 | Boehringer Ingelheim International Gmbh | Stabilized pharmaceutical formulations of a potent HCV inhibitor |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
-
2014
- 2014-03-14 US US14/214,477 patent/US9617310B2/en active Active
- 2014-03-14 JP JP2016503218A patent/JP6511432B2/ja active Active
- 2014-03-14 BR BR112015021768A patent/BR112015021768A2/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014233390A patent/AU2014233390B2/en active Active
- 2014-03-14 EP EP14723582.4A patent/EP2970335B1/en active Active
- 2014-03-14 WO PCT/US2014/029765 patent/WO2014145095A1/en not_active Ceased
- 2014-03-14 ES ES14723582T patent/ES2735355T3/es active Active
- 2014-03-14 CA CA2902569A patent/CA2902569A1/en not_active Abandoned
- 2014-03-14 EA EA201591456A patent/EA029088B1/ru not_active IP Right Cessation
- 2014-03-14 CN CN201480015589.0A patent/CN105073758B/zh active Active
- 2014-03-14 KR KR1020157028437A patent/KR102215400B1/ko active Active
- 2014-03-14 MX MX2015013224A patent/MX2015013224A/es unknown
- 2014-03-14 SG SG11201507223TA patent/SG11201507223TA/en unknown
-
2015
- 2015-08-18 IL IL240662A patent/IL240662A0/en unknown
-
2017
- 2017-03-10 US US15/455,508 patent/US20170313745A1/en not_active Abandoned
-
2018
- 2018-12-13 JP JP2018233621A patent/JP2019059775A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009005676A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1217196A1 (en) | 2016-12-30 |
| ES2735355T3 (es) | 2019-12-18 |
| EA029088B1 (ru) | 2018-02-28 |
| WO2014145095A1 (en) | 2014-09-18 |
| SG11201507223TA (en) | 2015-10-29 |
| CN105073758A (zh) | 2015-11-18 |
| US20140274884A1 (en) | 2014-09-18 |
| CN105073758B (zh) | 2017-08-11 |
| BR112015021768A2 (pt) | 2016-02-02 |
| EP2970335B1 (en) | 2019-05-08 |
| IL240662A0 (en) | 2015-10-29 |
| US20170313745A1 (en) | 2017-11-02 |
| US9617310B2 (en) | 2017-04-11 |
| AU2014233390A1 (en) | 2015-09-03 |
| JP2016516069A (ja) | 2016-06-02 |
| CA2902569A1 (en) | 2014-09-18 |
| JP6511432B2 (ja) | 2019-05-15 |
| AU2014233390B2 (en) | 2018-03-01 |
| EA201591456A1 (ru) | 2016-02-29 |
| MX2015013224A (es) | 2015-12-11 |
| EP2970335A1 (en) | 2016-01-20 |
| JP2019059775A (ja) | 2019-04-18 |
| KR20150130456A (ko) | 2015-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3492464B1 (en) | Intermediates for preparing inhibitors of hepatitis c virus | |
| KR102215400B1 (ko) | C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제 | |
| HK40009144A (en) | Intermediates for preparing inhibitors of hepatitis c virus | |
| HK40009144B (en) | Intermediates for preparing inhibitors of hepatitis c virus | |
| HK1217196B (en) | Macrocyclic and bicyclic inhibitors of hepatitis c virus | |
| HK1236517B (en) | Inhibitors of hepatitis c virus | |
| HK1236517A1 (en) | Inhibitors of hepatitis c virus | |
| HK1236517A (en) | Inhibitors of hepatitis c virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 6 |